Primmune Therapeutics is developing an orally administered TLR7 agonist to stimulate innate immunity in cancer immunotherapy. Their goal is to improve the response rate of patients to current and future immunotherapy medicines.

Biotechnology

Primmune Therapeutics

Primmune Therapeutics' headquarters in San Diego, CA, United States

Charles McDermott

James Appleman

Richard Daniels

Curtis Scribner

Paulo Rangel

Amir Nashat

Todd Harris

Elina Zuniga

Sheldon Morris

Jyoti Mayadev

Isan Chen

Andrew Rubinstein

Ezra Cohen

Tom Coll

The Leadership Team at Primmune Therapeutics is responsible for setting the strategic direction of the company, overseeing the development of its innovative TLR7 agonist therapies, and driving key operational and research initiatives. Comprising experienced executives in research and development, business operations, and manufacturing, the team collaborates to enhance the company's mission to improve cancer immunotherapy outcomes through cutting-edge immunological research.

Leadership Team

The Clinical Advisors Team at Primmune Therapeutics is responsible for providing expert guidance and insights to optimize the design and execution of clinical trials for the TLR7 agonist. They leverage their clinical expertise to assess patient needs, enhance trial protocols, and ensure the alignment of research objectives with regulatory requirements, ultimately aiming to improve patient outcomes in cancer immunotherapy.

Clinical Advisors Team

The Legal and Governance Team at Primmune Therapeutics is responsible for ensuring compliance with legal regulations and corporate governance standards. They provide strategic legal advice on intellectual property, contract management, and corporate policies, while also supporting the Board in decision-making processes and commercial strategy initiatives. This team's work is critical in safeguarding the company’s innovations and ensuring ethical operations as it advances its cancer therapies.

Legal and Governance Team

The Research and Development Team at Primmune Therapeutics focuses on advancing the discovery and optimization of their orally administered TLR7 agonist. This team collaborates closely to design and conduct preclinical studies, synthesize new compounds, and evaluate their efficacy in enhancing innate immunity for cancer treatment, ultimately aiming to improve patient response rates to immunotherapy.

Primmune Therapeutics

Org chart

Board & advisors

Teams

Leadership Team

Clinical Advisors Team

Legal and Governance Team

Research and Development Team

Offices

Primmune Therapeutics

Org chart

Board & advisors

Teams

Leadership Team

Clinical Advisors Team

Legal and Governance Team

Research and Development Team

Offices

Related companies